0 3 Low low JJ 4 20 CD3+CD28-induced cd3+cd28-induced JJ 21 34 interleukin-2 interleukin-2 NN 35 45 production production NN 46 56 correlates correlate VBZ 57 61 with with IN 62 71 decreased decrease VBN 72 80 reactive reactive JJ 81 87 oxygen oxygen NN 88 100 intermediate intermediate JJ 101 110 formation formation NN 111 113 in in IN 114 122 neonatal neonatal JJ 123 124 T t NN 125 130 cells cell NNS 130 131 . . . 133 136 The the DT 137 145 capacity capacity NN 146 148 of of IN 149 157 neonatal neonatal JJ 158 159 T t NN 160 165 cells cell NNS 166 168 to to TO 169 176 secrete secrete VB 177 190 interleukin-2 interleukin-2 NN 191 192 ( ( ( 192 196 IL-2 il-2 NN 196 197 ) ) ) 198 201 has have VBZ 202 206 been be VBN 207 215 reported report VBN 216 218 to to TO 219 221 be be VB 222 230 variable variable JJ 230 231 . . . 232 234 We we PRP 235 243 analysed analyse VBD 244 248 IL-2 il-2 NN 249 259 production production NN 260 262 in in IN 263 271 purified purify VBN 272 280 neonatal neonatal JJ 281 284 and and CC 285 290 adult adult JJ 291 292 T t NN 293 298 cells cell NNS 299 304 using use VBG 305 315 polyclonal polyclonal JJ 316 325 activator activator NN 326 333 phorbol phorbol NN 334 339 ester ester NN 340 341 + + SYM 342 349 calcium calcium NN 350 359 ionophore ionophore NN 360 361 ( ( ( 361 365 PDBu pdbu NN 366 367 + + SYM 368 372 iono iono NN 372 373 ) ) ) 374 376 or or CC 377 394 receptor-mediated receptor-mediated JJ 395 413 anti-CD3/anti-CD3+ anti-cd3/anti-cd3+ JJ 414 423 anti-CD28 anti-cd28 JJ 424 435 stimulation stimulation NN 435 436 . . . 437 441 PDBu pdbu NN 442 443 + + CC 444 448 iono iono NN 449 456 induced induce VBD 457 464 equally equally RB 465 469 high high JJ 470 474 IL-2 il-2 NN 475 481 levels level NNS 482 484 in in IN 485 489 both both CC 490 496 groups group NNS 497 500 and and CC 500 501 , , , 502 506 when when WRB 507 517 stimulated stimulate VBN 518 522 with with IN 523 534 plate-bound plate-bound JJ 535 543 anti-CD3 anti-cd3 JJ 544 554 monoclonal monoclonal JJ 555 563 antibody antibody NN 564 565 ( ( ( 565 568 mAb mab NN 568 569 ) ) ) 569 570 , , , 571 574 the the DT 575 579 IL-2 il-2 NN 580 589 secretion secretion NN 590 592 by by IN 593 601 neonatal neonatal JJ 602 607 cells cell NNS 608 611 was be VBD 612 624 undetectable undetectable JJ 625 628 and and CC 629 634 adult adult JJ 635 640 cells cell NNS 641 649 produced produce VBD 650 653 low low JJ 654 661 amounts amount NNS 662 664 of of IN 665 669 IL-2 il-2 NN 670 671 ( ( ( 671 675 mean mean NN 676 679 331 331 CD 680 683 +/- +/- SYM 684 686 86 86 CD 687 692 pg/ml pg/ml NN 692 693 ) ) ) 693 694 . . . 695 698 The the DT 699 707 addition addition NN 708 710 of of IN 711 720 anti-CD28 anti-cd28 JJ 721 724 mAb mab NN 725 727 to to TO 728 747 anti-CD3-stimulated anti-cd3-stimulated JJ 748 753 cells cell NNS 754 762 markedly markedly RB 763 772 increased increase VBD 773 777 IL-2 il-2 NN 778 788 production production NN 789 791 in in IN 792 796 both both DT 797 801 cell cell NN 802 807 types type NNS 807 808 , , , 809 812 but but CC 813 819 levels level NNS 820 822 of of IN 823 827 IL-2 il-2 NN 828 830 in in IN 831 839 neonatal neonatal JJ 840 841 T t NN 842 847 cells cell NNS 848 856 remained remain VBD 857 864 clearly clearly RB 865 870 lower low JJR 871 875 than than IN 876 881 those those DT 882 884 of of IN 885 890 adult adult JJ 891 892 T t NN 893 898 cells cell NNS 899 900 ( ( ( 900 910 respective respective JJ 911 915 mean mean JJ 916 922 values value NNS 922 923 : : : 924 927 385 385 CD 928 931 +/- +/- CC 932 935 109 109 CD 936 941 pg/ml pg/ml NN 942 945 and and CC 946 950 4494 4494 CD 951 954 +/- +/- SYM 955 959 1199 1199 CD 960 965 pg/ml pg/ml NN 965 966 ) ) ) 966 967 . . . 968 970 As as IN 971 979 NF-kappa NF-kappa NNP 980 981 B B NNP 982 984 is be VBZ 985 986 a a DT 987 995 critical critical JJ 996 1009 transcription transcription NN 1010 1016 factor factor NN 1017 1019 in in IN 1020 1023 the the DT 1024 1031 control control NN 1032 1034 of of IN 1035 1039 IL-2 il-2 NN 1040 1050 expression expression NN 1050 1051 , , , 1052 1054 we we PRP 1055 1059 next next RB 1060 1068 analysed analyse VBD 1069 1072 its its PRP$ 1073 1080 nuclear nuclear JJ 1081 1094 translocation translocation NN 1095 1097 in in IN 1098 1106 neonatal neonatal JJ 1107 1110 and and CC 1111 1116 adult adult JJ 1117 1118 T t NN 1119 1124 cells cell NNS 1125 1130 using use VBG 1131 1134 the the DT 1135 1150 electrophoretic electrophoretic JJ 1151 1159 mobility mobility NN 1160 1165 shift shift NN 1166 1171 assay assay NN 1172 1175 and and CC 1175 1176 , , , 1177 1184 because because IN 1185 1194 induction induction NN 1195 1197 of of IN 1198 1206 reactive reactive JJ 1207 1213 oxygen oxygen NN 1214 1227 intermediates intermediate NNS 1228 1229 ( ( ( 1229 1232 ROI ROI NNP 1232 1233 ) ) ) 1234 1236 is be VBZ 1237 1245 required require VBN 1246 1249 for for IN 1250 1253 the the DT 1254 1264 activation activation NN 1265 1267 of of IN 1268 1276 NF-kappa NF-kappa NNP 1277 1278 B B NNP 1278 1279 , , , 1280 1282 we we PRP 1283 1287 also also RB 1288 1296 analysed analyse VBD 1297 1303 levels level NNS 1304 1306 of of IN 1307 1320 intracellular intracellular JJ 1321 1324 ROI ROI NNP 1325 1327 in in IN 1328 1333 these these DT 1334 1339 cells cell NNS 1340 1345 using use VBG 1346 1349 the the DT 1350 1362 ROI-reactive roi-reactive JJ 1363 1375 fluorochrome fluorochrome NN 1376 1383 DCFH-DA dcfh-da NN 1384 1387 and and CC 1388 1392 flow flow NN 1393 1402 cytometry cytometry NN 1402 1403 . . . 1404 1406 In in IN 1407 1415 neonatal neonatal JJ 1416 1417 T t NN 1418 1423 cells cell NNS 1424 1432 NF-kappa NF-kappa NNP 1433 1434 B B NNP 1435 1445 activation activation NN 1446 1449 and and CC 1450 1453 ROI ROI NNP 1454 1463 formation formation NN 1464 1469 after after IN 1470 1478 anti-CD3 anti-cd3 JJ 1479 1490 stimulation stimulation NN 1491 1495 were be VBD 1496 1499 low low JJ 1500 1508 compared compare VBN 1509 1513 with with IN 1514 1519 adult adult JJ 1520 1521 T t NN 1522 1527 cells cell NNS 1528 1531 and and CC 1531 1532 , , , 1533 1541 although although IN 1542 1550 addition addition NN 1551 1553 of of IN 1554 1563 anti-CD28 anti-cd28 JJ 1564 1567 mAb mab NN 1568 1577 increased increase VBD 1578 1587 induction induction NN 1588 1590 of of IN 1591 1599 NF-kappa NF-kappa NNP 1600 1601 B B NNP 1602 1605 and and CC 1606 1609 ROI ROI NNP 1610 1619 formation formation NN 1619 1620 , , , 1621 1627 levels level NNS 1628 1635 similar similar JJ 1636 1638 to to TO 1639 1644 those those DT 1645 1647 of of IN 1648 1654 adults adult NNS 1655 1659 were be VBD 1660 1663 not not RB 1664 1672 achieved achieve VBN 1672 1673 . . . 1674 1679 After after IN 1680 1684 PDBu pdbu NN 1685 1686 + + CC 1687 1691 iono iono NN 1692 1703 stimulation stimulation NN 1703 1704 , , , 1705 1708 the the DT 1709 1714 cells cell NNS 1715 1721 showed show VBD 1722 1729 similar similar JJ 1730 1733 ROI ROI NNP 1734 1743 formation formation NN 1744 1747 and and CC 1748 1752 IL-2 il-2 NN 1753 1762 secretion secretion NN 1762 1763 . . . 1764 1767 Our our PRP$ 1768 1775 results result NNS 1776 1783 suggest suggest VBP 1784 1788 that that IN 1789 1796 reduced reduce VBN 1797 1801 IL-2 il-2 NN 1802 1812 production production NN 1813 1815 by by IN 1816 1824 neonatal neonatal JJ 1825 1826 T t NN 1827 1832 cells cell NNS 1833 1835 is be VBZ 1836 1844 specific specific JJ 1845 1848 for for IN 1849 1857 anti-CD3 anti-cd3 JJ 1858 1861 and and CC 1862 1871 anti-CD3+ anti-cd3+ JJ 1872 1890 anti-CD28-mediated anti-cd28-mediated JJ 1891 1902 stimulation stimulation NN 1903 1906 and and CC 1907 1911 that that IN 1912 1917 these these DT 1918 1928 activators activator NNS 1929 1935 cannot cannot MD 1936 1947 effectively effectively RB 1948 1956 activate activate VB 1957 1960 the the DT 1961 1973 ROI-NF-kappa ROI-NF-kappa NNP 1974 1975 B B NNP 1976 1986 signalling signalling NN 1987 1994 pathway pathway NN 1995 1997 in in IN 1998 2006 neonatal neonatal JJ 2007 2008 T t NN 2009 2014 cells cell NNS 2014 2015 . . .